Treatment Clinical Trials for Esophageal Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for esophageal cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 79

  • A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors

    This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Avelumab and Chemoradiation in Treating Patients with Stage II-III Esophageal Cancer That Can Be Removed by Surgery

    This phase I / II trial studies the side effects of avelumab when given together with chemoradiation in treating patients with stage II-III esophageal cancer that can be removed by surgery. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy with radiation therapy may kill more tumor cells. Giving avelumab and chemoradiation may work better in treating patients with esophageal cancer.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Proton Beam Radiation Therapy in Treating Patients with Stage II or III Esophageal Cancer

    This phase II trial studies how well proton beam radiation therapy works in treating patients with stage II or III esophageal cancer. Proton beam radiation therapy uses high energy protons to kill tumor cells and shrink tumors while causing less damage to healthy tissues and organs.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

    The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line treatment in patients with advanced unresectable / metastatic ESCC that has progressed during or after first line therapy.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • M7824 in Subjects With HPV Associated Malignancies

    Background: In the United States, each year there are more than 30,000 cases of human papillomavirus (HPV) associated cancers. Some of these cancers are often incurable and are not improved by standard therapies. Researchers want to see if a new drug M7824, which targets and blocks a pathway that prevents the immune system from effectively fighting the cancer can shrink tumors in people with some HPV cancers. Objectives: To see if the drug M7824 causes tumors to shrink. Eligibility: Adults age 18 and older who have a cancer associated with HPV infection. Design: Participants will be screened with medical history and physical exam. They will review their symptoms and how they perform normal activities. They will have body scans. They will give blood and urine samples. They will have a sample of their tumor tissue taken if one is not available. Participants will have an electrocardiogram to evaluate their heart. Then they will get the study drug through a thin tube in an arm vein. Participants will get the drug every 2 weeks for 26 times (1 year). This is 1 course. After the course, participants will be monitored but will not take the study drug. If their condition gets worse, they will start another course with the drug. This process can be repeated as many times as needed. Treatment will stop if the participant has bad side effects or the drug stops working. Throughout the study, participants will repeat some or all the screening tests. After participants stop taking the drug, they will have a follow-up visit and repeat some screening tests. They will get periodic follow-up phone calls. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Basket Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and / or Metastatic Solid Tumors

    This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of RO6874281 in combination with atezolizumab in participants with advanced and / or metastatic solid tumors. Currently the focus is on patients with Head and Neck, oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.
    Location: 2 locations

  • Pembrolizumab, Oxaliplatin, Capecitabine as First Line Treatment for Patients with Recurrent or Metastatic Esophagus or Stomach Cancer

    This phase II trial studies how well pembrolizumab, oxaliplatin, and capecitabine work as first-line treatment in treating patients with esophagus or stomach cancer that has come back or spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, oxaliplatin, and capecitabine may work better in treating patients with esophagus or stomach cancer.
    Location: Duke University Medical Center, Durham, North Carolina

  • Endoesophageal Brachytherapy Using a 6-Channel Balloon Repositioning, Multichannel Applicator in Treating Participants with Esophageal Carcinoma

    This trial studies how well endoesophageal brachytherapy using a 6-channel balloon repositioning, multichannel applicator works in treating in participants with esophageal carcinoma. A 6-channel balloon repositioning, multichannel applicator may work by making the dose more evenly distributed and reducing "hot spots" of radiation (doses above the prescription dose) in the esophageal wall during radiation therapy.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

    This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.
    Location: Duke University Medical Center, Durham, North Carolina

  • Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

    This is a single-arm phase I / Ib study of crenolanib combined with ramucirumab / paclitaxel as second line therapy for patients with advanced / metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • APX005M, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Esophageal Cancer or Gastroesophageal Junction Cancer that Can Be Removed by Surgery

    This pilot phase II trial studies the side effects of CD40 agonistic monoclonal antibody APX005M (APX005M), chemotherapy, and radiation therapy, and to see how well they work when given before surgery in treating patients with esophageal cancer or gastroesophageal cancer that can be removed by surgery. APX005M is intended to stimulate the body’s own immune system so that the immune cells can more effectively invade and destroy the tumor, adding to the benefits of the chemotherapy and radiation therapy. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving APX005M, chemotherapy, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer

    This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic). Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Surgery, such as complete surgical resection, may stop the spread of tumor cells by surgically removing organs or tumors. Giving chemotherapy with radiation or surgery may work better than chemotherapy alone in treating participants with oligometastatic esophageal or gastric cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vascular-Targeted Photodynamic Therapy with Padeliporfin in Treating Dysphagia in Patients with Stage IV Esophageal Cancer

    This phase I trial studies the side effects and best dose of vascular-targeted photodynamic therapy with padeliporfin in treating dysphagia in patients with stage IV esophageal cancer. Padeliporfin is a photosensitizing drug which stays in the blood vessels and becomes active when exposed to light. Vascular-targeted photodynamic therapy uses a laser to activate padeliporfin and may kill tumor cells and improve swallowing in patients with esophageal cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Pulsed Low Dose Radiation Therapy and Chemotherapy in Reducing the Rates of Severe Acute Esophagitis in Patients with Stage IIIA Non-small Cell Lung Cancer and Stage IB-IIIC Esophageal Cancer

    This phase I trial studies how well pulsed low dose radiation therapy and chemotherapy work in reducing the rates of severe acute esophagitis in patients with stage IIIA non-small cell lung cancer and stage IB-IIIC esophageal cancer. Pulsed low dose rate radiation therapy uses short pulses to deliver low doses of radiation for extended times and may reduce the rate of severe acute esophagitis in patients with lung and esophageal cancer.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • Pembrolizumab in Treating Patients with Locally Advanced Esophageal and Gastric Cancer

    This phase II clinical trial studies the side effects of pembrolizumab in treating patients with esophageal and gastric cancer that has spread from where it started to nearby tissue or lymph node. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Duke University Medical Center, Durham, North Carolina

  • Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

    This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

    Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect. It was discovered that only people with certain genes got this side effect. Researchers want to test mithramycin in people who do not have those certain genes. Objectives: To find the highest safe dose of mithramycin that can be given to people with chest cancer who have certain genes over 24 hours instead of spread out over a longer period of time. To see if mithramycin given as a 24-hour infusion shrinks tumors. Eligibility: People ages 18 and older who have chest cancer that is not shrinking with known therapies, and whose genes will limit the chance of liver damage from mithramycin Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Lung and heart function tests X-rays or scans of their tumor Liver ultrasound Tumor biopsy Participants will be admitted to the hospital overnight. A small plastic tube (catheter) will be inserted in the arm or chest. They will get mithramycin through the catheter over about 24 hours. If they do not have bad side effects or their cancer does not worsen, they can repeat the treatment every 14 days. Participants will have multiple visits for each treatment cycle. These include repeats of certain screening tests. After stopping treatment, participants will have weekly visits until they recover from any side effects.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Pembrolizumab and Palliative Radiation Therapy in Treating Patients with Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

    This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Palliative radiation therapy, such as external beam radiation therapy, uses high energy beams to treat symptoms that are caused by tumors. Giving pembrolizumab together with palliative radiation therapy may work better in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Proton Beam Radiation Therapy, Carboplatin, and Paclitaxel in Treating Patients with Stage IIB-IIIC Esophageal Cancer

    This phase I trial studies the side effects and best dose of proton beam radiation therapy given together with carboplatin and paclitaxel in treating patients with stage IIB-IIIC esophageal cancer. Proton beam radiation therapy uses high-energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving proton beam radiation therapy with carboplatin and paclitaxel may work better in treating patients with esophageal cancer.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Mithramycin for Lung, Esophagus, and Other Chest Cancers

    Background: - Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: - To see if mithramycin is safe and effective against different chest cancers. Eligibility: - Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum cancers. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment. - Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each 14-day round of treatment is called a cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of a combined vaccine therapy and to see how well it works in treating patients with solid tumors that have spread to other parts of the body (metastatic). The cancer vaccine is made up of two proteins (that look like the tumor cells) mixed up with a special compound that may help train and boost the immune system to recognize and fight the tumor cells.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

    This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

    The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first line treatment in combination with chemotherapy in patients with advanced unresectable / metastatic ESCC.
    Location: 2 locations

  • Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

    The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
    Location: M D Anderson Cancer Center, Houston, Texas